Side-by-side · Research reference

SemaglutidevsSermorelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedVerified15/53 cited

BPhase 3Reviewed14/43 cited

Semaglutide

GLP-1 RA · FDA-Approved

0.25–2.4 mgWeekly doseWEGOVY (semaglutide) injection 2021

14.9%Body-weight ↓Wilding 2021

~7 daysHalf-lifeWEGOVY (semaglutide) injection 2021

SQ · Abdomen / thigh / arm · Once weekly

Sermorelin

GHRH 1-29 fragment · Short-acting

100–500 mcgPer doseMolteno 2013

Phase 3Evidence levelWalker 1994 Molteno 2013

~12 minHalf-lifeMolteno 2013

SQ · Pre-sleep · 1×/day

01Mechanism of Action

Parameter

Semaglutide

Sermorelin

Primary target

GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021

Pituitary GHRH receptorWalker 1994

Pathway

GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021

GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisWalker 1994

Downstream effect

Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021

Pulsatile GH release; subsequent IGF-1 elevationMolteno 2013

Feedback intact?

Glucose-dependent insulin release preserves physiological feedback

Yes — short pulse preserves feedback

Origin

Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021

Unmodified active 29-AA fragment of human GHRH (1-44)Walker 1994

Antibody development

—

02Dosage Protocols

Parameter

Semaglutide

Sermorelin

Standard dose (T2D, Ozempic)

0.5–1.0 mg / weekWEGOVY (semaglutide) injection 2021

—

Standard dose (weight, Wegovy)

2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021 Wilding 2021

—

Frequency

Once weekly, same day each week

Once daily, pre-sleep

Titration schedule

0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks

Mitigates GI side effects.

—

Evidence basis

FDA-approved · Phase 3 RCTsWilding 2021 WEGOVY (semaglutide) injection 2021

Phase 3 (Geref pediatric); clinical practiceWalker 1994 Molteno 2013

Duration

Indefinite for chronic indication

Discontinuation results in weight regain.

8–12 weeks per cycle

Reconstitution

Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.

Bacteriostatic water

Timing

Any time of day, with or without food

Pre-sleep, fasted preferred

Half-life

~7 days (168 h)WEGOVY (semaglutide) injection 2021

~12 min (plasma)Molteno 2013

Shorter than tesamorelin (~26 min) — simpler GHRH analogue.

Standard dose

—

100–500 mcg per injectionMolteno 2013

Lower / starter dose

—

100 mcg per dose

04Side Effects & Safety

Parameter

Semaglutide

Sermorelin

GI symptoms

Nausea, vomiting, diarrhea, constipation (very common)Wilding 2021

—

Injection site reaction

Mild erythema, pruritus

Mild erythema, transient pain

Pancreatitis risk

Rare; discontinue if suspectedWEGOVY (semaglutide) injection 2021

—

Thyroid C-cell tumours

Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021

—

Hypoglycemia

Low risk as monotherapy; elevated when combined with sulfonylureas / insulin

—

Gallbladder events

Increased cholelithiasis

—

Pregnancy / OB

ContraindicatedWEGOVY (semaglutide) injection 2021

Avoid

Heart rate

Modest ↑ resting HR (~2-4 bpm)

—

Flushing / headache

—

Common transient effect

IGF-1 elevation

—

Modest at standard doses

Cancer risk

—

Contraindicated in active malignancy (GH/IGF-1 axis)

Glucose handling

—

Generally neutral

Absolute Contraindications

Semaglutide

·Personal or family history of medullary thyroid carcinoma
·Multiple endocrine neoplasia syndrome type 2
·Pregnancy / breastfeeding
·Hypersensitivity to semaglutide

Sermorelin

·Active malignancy
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Relative Contraindications

Semaglutide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy (may worsen with rapid glycemic improvement)

Sermorelin

·Untreated diabetes

05Administration Protocol

Parameter

Semaglutide

Sermorelin

1. Reconstitution / device

Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.

2. Injection site

SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.

SQ — abdomen or thigh. Rotate sites.

3. Timing

Once weekly, same day. Day can be changed if ≥2 days separate doses.

Pre-sleep, fasted.

4. Storage

Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Needle

Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

Semaglutide

+ Tirzepatide

Weak

View Tirzepatide →

Combining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.

Note: Stack not recommended — choose one GLP-1 RA
Primary benefit: (none — additive toxicity, no synergy)

Sermorelin

+ Ipamorelin

Strong

View Ipamorelin →

Sermorelin (GHRH analogue) and ipamorelin (selective GHRP) form the prototypical GHRH+GHRP dual-axis stack at the lowest cost. Both peak within 30 min and produce a sharp physiological GH pulse without cortisol/prolactin elevation.

Sermorelin: 200–300 mcg SQ · pre-sleep
Ipamorelin: 200–300 mcg SQ · same injection
Primary benefit: Pulsatile GH stimulation, recovery, body composition

Raun 1998 Walker 1994